

# Botulinum toxin: an adjunct in limb reconstruction - Can it reduce pain and joint complications in the lengthening phase?

<b>Submission date</b>	<b>Recruitment status</b>	<input checked="" type="checkbox"/> Prospectively registered
18/02/2008	Stopped	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
19/02/2008	Stopped	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
30/01/2020	Surgery	<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr James A Fernandes

### Contact details

Sheffield Children's Hospital  
Western Bank  
Sheffield  
United Kingdom  
S10 2TH

## Additional identifiers

### ClinicalTrials.gov (NCT)

NCT00624299

### Protocol serial number

SCH-07-006; Sponsor ref: 7860

## Study information

### Scientific Title

Botulinum toxin: an adjunct in limb reconstruction - Can it reduce pain and joint complications in the lengthening phase?

## **Acronym**

Botox

## **Study objectives**

The surgery to correct leg and foot deformities in children is a lengthy, and sometimes, difficult procedure. Metal frames are attached to the leg and/or foot and over a period of time the frame is manipulated to obtain the corrected position. During this period the muscles and skin become very tight which causes pain and may pull the joint out of position. When this happens it is sometimes necessary to stop the treatment before the best position is obtained. This means that not only is the child left with an inadequate result but that further surgery is required in the future. If the tension could be removed whilst the treatment is underway this would reduce the pain, the possibility of joint damage and potentially allow a more satisfactory to be obtained without the need for further surgery.

Botulinum toxin or Botox®, as it is commonly called, has the potential to temporarily reduce the tension in the muscles without causing permanent damage.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

An application has been submitted to the North Sheffield Research Ethics Office. Approval pending as of 18/02/2008.

## **Study design**

Patient/assessor-blinded, pilot, randomised controlled trial.

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Limb reconstruction surgery

## **Interventions**

Patients and the researcher collecting data will be blinded to the allocation of treatment.

Intervention group: Botulinum toxin intramuscular injections, 4 units per kg body weight

Control group: Saline injections

## **Intervention Type**

Drug

## **Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Botulinum toxin (Botox®)

**Primary outcome(s)**

Pain levels using a visual analogue scale validated at the Sheffield Children's Hospital. Following discharge from hospital, patients will be asked to continue recording pain level three times a day for 18 month or until discharged i.e. end of episode, which ever is first.

**Key secondary outcome(s)**

1. Range of movement in affected joints measured by a goniometre, recorded at each clinic visit until one month from the end of lengthening
2. Walking measured using a pedometer, recorded at each clinic visit until one month from the end of lengthening
3. Scores of the Child Health Questionnaire and the Pediatric Outcome Data Collection Instrument, administered pre-operatively, one month post-lengthening completion and one year from surgery

**Completion date**

01/04/2010

**Reason abandoned (if study stopped)**

Lack of funding/sponsorship

## Eligibility

**Key inclusion criteria**

1. Any child having reconstruction surgery which involves the distraction of bone and or soft tissue for femoral or tibial deformity and congenital talipes equinovarus.
2. Children between the ages of 6 and 18 years attending the Sheffield Children's NHS Trust

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Sex**

All

**Key exclusion criteria**

Children with neurological aetiology

**Date of first enrolment**

01/04/2008

**Date of final enrolment**

01/04/2010

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

**Sheffield Children's Hospital**

Sheffield

United Kingdom

S10 2TH

# Sponsor information

## Organisation

Sheffield Children's NHS Foundation Trust (UK)

## ROR

<https://ror.org/02md8hv62>

# Funder(s)

## Funder type

Charity

## Funder Name

Sheffield Hospitals NHS Charitable Trust (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type

Details

Date created Date added Peer reviewed? Patient-facing?

